| Trial ID # | NCT00072566 |
| Phase | II |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Cyclophosphamide, Bevacizumab |
| Eligible Participant | Recurrent ovarian cancer with ≤3 prior therapies |
| Patients Enrolled | 70, median 2 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DoR, PFS, evaluated per RECIST |
| Efficacy | ORR: 24% (17PR, n=70) |
| Clinically Significant Adverse Events | Serious AE: three deaths, two pulmonary hypertension, one gastrointestinal perforation |
| Conclusion | Promising response rates of bevacizumab+cyclophosphamide combination |
| Reference | Garcia AA et al. Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol (2008) 26(1): 76-82 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.